Jeremy Kieval, MD
Ophthalmology · Lexington, MANPI 1457537136
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $141,310 of the $232,010 with a category attached, or 60.9%. Johnson & Johnson Surgical Vision, Inc. accounts for 63.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $116,513 and has fallen 100.0% since, to $54 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $1040.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$147K
- Dompe US, Inc.$27K
- Kala Pharmaceuticals, Inc.$20K
- Sun Pharmaceutical Industries Inc.$10K
- Shire North American Group Inc$9K
- Novartis$9K
- plus $10K from 12 others
What the payments were for
- Consulting fees$141,31061%
- Speaking & faculty fees$64,55828%
- Travel & lodging$19,2798%
- Food & beverage$6,8633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 99 | $146,645 |
| Dompe US, Inc. | 10 | $26,897 |
| Kala Pharmaceuticals, Inc. | 29 | $19,813 |
| Sun Pharmaceutical Industries Inc. | 12 | $10,365 |
| Shire North American Group Inc | 12 | $9,092 |
| Novartis | 10 | $8,726 |
| Ocular Therapeutix, Inc. | 7 | $2,253 |
| Carl Zeiss Meditec, Inc. | 7 | $1,986 |
| Seagen Inc. | 1 | $1,800 |
| Alcon Research LLC | 1 | $1,750 |
| NEW World Medical,inc. | 3 | $825 |
| Biotissue Holdings Inc. | 21 | $753 |
| Lensar, Inc. | 1 | $700 |
| Alcon | 6 | $266 |
| Glaukos Corporation | 1 | $68 |
| Carl Zeiss Meditec USA, Inc. | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$132,544
- Tecnis Symfony IOL$59,129
- Tecnis Multifocal Family of 1-piece IOLS$58,252
- Whitestar Phacoemulsficiation System$56,384
- Whitestar Signature$51,218
- Oxervate$26,798
- XIIDRA$17,433
- INVELTYS$15,307
- CEQUA$10,095
- Tecnis Simplicity$5,728
- EYSUVIS$4,100
- VERITAS Vision System$2,677
- DEXTENZA$2,385
- Tecnis 1-piece IOL$1,868
- TIVDAK$1,800
- AcrySof IQ VIVITY IOL$1,750
- VERACITY SURGICAL$1,632
- CATALYS SYSTEM$1,329
- QUATERA 700$882
- Tecnis Symfony Toric IOL$878
How this compares
$232,010 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $77,601 |
| XiidraLifitegrast | 15 | $29,907 |
| Bromfenac Sodium | 78 | $14,690 |
| Loteprednol Etabonate | 61 | $10,989 |
| ProlensaBromfenac Sodium | 26 | $9,572 |
| Prednisolone Acetate | 183 | $9,464 |
| Cyclosporine | 15 | $8,457 |
| InveltysLoteprednol Etabonate | 16 | $4,751 |
| MoxifloxacinMoxifloxacin Hcl | 157 | $3,556 |
| Latanoprost | 146 | $2,062 |
| Brimonidine Tartrate | 23 | $1,972 |
| Timolol Maleate | 59 | $1,649 |
| ValacyclovirValacyclovir Hcl | 28 | $1,541 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 31 | $429 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kala Pharmaceuticals, Inc.Inveltys | $19,813 | $4,75116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Lexington
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jonathan TalamoWaltham$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.